PT87562A - Procede de expression de la proapolipoproteine a-i humaine - Google Patents

Procede de expression de la proapolipoproteine a-i humaine

Info

Publication number
PT87562A
PT87562A PT87562A PT8756288A PT87562A PT 87562 A PT87562 A PT 87562A PT 87562 A PT87562 A PT 87562A PT 8756288 A PT8756288 A PT 8756288A PT 87562 A PT87562 A PT 87562A
Authority
PT
Portugal
Prior art keywords
sequence
expression
expression vectors
proapolipoproteine
humaine
Prior art date
Application number
PT87562A
Other languages
English (en)
Other versions
PT87562B (pt
Inventor
Alex Bollen
Jean Gobert
Ernst Wulfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of PT87562A publication Critical patent/PT87562A/pt
Publication of PT87562B publication Critical patent/PT87562B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT87562A 1987-05-28 1988-05-24 Processo para expressao de proapolipoproteina a-i humana PT87562B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (2)

Publication Number Publication Date
PT87562A true PT87562A (pt) 1989-05-31
PT87562B PT87562B (pt) 1992-09-30

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87562A PT87562B (pt) 1987-05-28 1988-05-24 Processo para expressao de proapolipoproteina a-i humana

Country Status (33)

Country Link
US (1) US5059528A (pt)
EP (1) EP0293357B1 (pt)
JP (1) JP2634193B2 (pt)
KR (1) KR970000808B1 (pt)
CN (1) CN1031892C (pt)
AT (1) ATE89006T1 (pt)
AU (1) AU615654B2 (pt)
CA (1) CA1323851C (pt)
CY (1) CY1809A (pt)
CZ (1) CZ283648B6 (pt)
DD (1) DD291093A5 (pt)
DE (1) DE3880739T2 (pt)
DK (1) DK175686B1 (pt)
EG (1) EG19101A (pt)
ES (1) ES2054878T3 (pt)
FI (1) FI100056B (pt)
GB (1) GB8712540D0 (pt)
HK (1) HK137794A (pt)
HU (1) HU204562B (pt)
IE (1) IE62422B1 (pt)
IL (1) IL86480A (pt)
LT (1) LT3600B (pt)
LV (1) LV5288A3 (pt)
NO (1) NO179253C (pt)
NZ (1) NZ224808A (pt)
PL (1) PL158064B1 (pt)
PT (1) PT87562B (pt)
RU (1) RU2009198C1 (pt)
SG (1) SG131594G (pt)
SK (1) SK363888A3 (pt)
SU (1) SU1834904A3 (pt)
UA (1) UA19765A (pt)
ZA (1) ZA883824B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
EP0345155B1 (en) * 1988-05-31 1994-08-10 Mitsubishi Kasei Corporation Process for producing natural human apolipoprotein e-like proteins
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
ATE158816T1 (de) * 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
WO1992010760A1 (en) * 1990-11-30 1992-06-25 Monoclonetics International, Incorporated Methods for the diagnosis of chronic lower back and cervical pain
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
CA2431210A1 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
KR20080049066A (ko) * 2005-08-26 2008-06-03 세레니스 쎄라퓨틱스 홀딩 에스에이 유산균에서의 아포지단백질 유전자 생성물의 생성을 위한조성물 및 방법
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
ES2727549T3 (es) * 2008-10-03 2019-10-17 Curna Inc Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
CA3039251C (en) 2008-11-10 2024-01-09 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
LT2440183T (lt) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Patobulinta lipido kompozicija
EP2464336A4 (en) 2009-08-14 2013-11-20 Alnylam Pharmaceuticals Inc COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
ES2749426T3 (es) 2009-12-18 2020-03-20 Univ British Columbia Métodos y composiciones para administración de ácidos nucleicos
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
CN103096875B (zh) 2010-06-03 2016-08-17 阿尔尼拉姆医药品有限公司 用于递送活性剂的生物可降解脂质
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
EP3456317A1 (en) 2011-09-27 2019-03-20 Alnylam Pharmaceuticals, Inc. Di-aliphatic substituted pegylated lipids
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
RU2650510C2 (ru) 2013-05-01 2018-04-16 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии аполипопротеина c-iii
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
US11492616B2 (en) * 2016-10-27 2022-11-08 Institute Of Microbiology, Chinese Academy Of Sciences Method for modifying amino acid attenuator and use of same in production
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding CARGOMÈRES
EP3668549B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Apomers
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
CA3177243A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
MX2023003877A (es) 2020-10-01 2023-04-18 Abionyx Pharma Sa Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
BE901119A (fr) 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
AU6522486A (en) 1985-10-04 1987-04-24 Biotechnology Research Partners Limited Recombinant apolipoproteins and methods
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
AU8273987A (en) * 1986-10-29 1988-05-25 Biotechnology Research Partners Limited Apoai-ciii-aiv, apoaii apob , apoci, and ldl receptor polymorphisms for genetic fingerprinting and predictive of atherosclerosis

Also Published As

Publication number Publication date
AU615654B2 (en) 1991-10-10
LTIP828A (en) 1995-02-27
DK175686B1 (da) 2005-01-17
HK137794A (en) 1994-12-16
NO179253C (no) 1996-09-04
HU204562B (en) 1992-01-28
DK289688A (da) 1988-11-29
NO179253B (no) 1996-05-28
JPS6416589A (en) 1989-01-20
JP2634193B2 (ja) 1997-07-23
SK279166B6 (sk) 1998-07-08
EP0293357B1 (fr) 1993-05-05
FI882456A (fi) 1988-11-29
IL86480A0 (en) 1988-11-15
IL86480A (en) 1992-08-18
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
UA19765A (uk) 1997-12-25
HUT47153A (en) 1989-01-30
LT3600B (en) 1995-12-27
FI882456A0 (fi) 1988-05-25
SG131594G (en) 1995-01-13
CY1809A (en) 1995-10-20
KR880014110A (ko) 1988-12-22
IE881597L (en) 1988-11-28
NO882341L (no) 1988-11-29
DD291093A5 (de) 1991-06-20
PT87562B (pt) 1992-09-30
DE3880739T2 (de) 1993-08-19
LV5288A3 (lv) 1993-10-10
SU1834904A3 (ru) 1993-08-15
IE62422B1 (en) 1995-02-08
EP0293357A1 (fr) 1988-11-30
NZ224808A (en) 1990-01-29
CN1031892C (zh) 1996-05-29
RU2009198C1 (ru) 1994-03-15
CZ363888A3 (cs) 1998-02-18
NO882341D0 (no) 1988-05-27
CZ283648B6 (cs) 1998-05-13
CA1323851C (en) 1993-11-02
KR970000808B1 (en) 1997-01-20
CN88103118A (zh) 1988-12-14
AU1672388A (en) 1988-12-01
ATE89006T1 (de) 1993-05-15
FI100056B (fi) 1997-09-15
US5059528A (en) 1991-10-22
DE3880739D1 (de) 1993-06-09
PL158064B1 (pl) 1992-07-31
ES2054878T3 (es) 1994-08-16
PL272698A1 (en) 1989-03-06
EG19101A (en) 1994-09-29
SK363888A3 (en) 1998-07-08
ZA883824B (en) 1989-02-22

Similar Documents

Publication Publication Date Title
PT87562A (pt) Procede de expression de la proapolipoproteine a-i humaine
ES2059354T3 (es) Un metodo para producir un polipeptido.
ES2089044T3 (es) Fragmento de dna que codifica un polipeptido que presenta actividad nitrilo hidratasa, un transformante que contiene el fragmento de dna y un proceso para la produccion de amidas utilizando el transformante.
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
DK128490D0 (da) Renset gensekvens, som koder for protein ia, ib eller begge fra neisseria gonorrhoeae, rekombinantvektorer og organismer indeholdende sekvenser, dens fremstilling og anvendelse, neisseria-stamme og dennes paavisning
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
DK27097A (da) Minactivin og fremgangsmåde til fremstilling deraf
DE3856392D1 (de) Klonierung von Malaria-spezifischen DNA-Sequenzen:Isolierung des Gens für das 140 kd Protein
DE69636737D1 (de) Neues immunoregulatorisches protein lst-1
TH5997EX (th) การสร้างโปรอโปดิโปรโปรตีน a-i ของคนโดยการแสดงออกของรหัสพันธุกรรม

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19920310

PC3A Transfer or assignment

Free format text: 20010108 MINISTERE DE LA REGION WALLONNE BE

TE3A Change of address (patent)

Owner name: UCB, S.A.

Effective date: 20010126

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20030930